Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

In this new paper, the authors describe Immune-Modified Response Evaluation in Solid Tumors (imRECIST).


Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.

In this new paper, published in the Journal of Clinical Oncology, the authors describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses:

DOI: 10.1200/JCO.2017.75.1644 Journal of Clinical Oncology - published online before print January 17, 2018

Dr Alison Halliday

Community Manager, Nature Research

Molecular Biologist turned freelance science communicator, with 10 year's experience at Cancer Research UK.